Illumina prevails over FTC's challenge of $8B Grail buyout
An administrative judge ruled Illumina’s $8 billion acquisition of cancer-testing company Grail didn’t violate antitrust law, Illumina said on Thursday.
A Federal Trade Commission lawsuit threatened to unwind Illumina’s acquisition of Grail, a blood testing company that screens for cancers at an early stage.
“As we’ve stated from the outset, this transaction is procompetitive, will advance innovation, lower healthcare costs and save lives,” Illumina general counsel Charles Dadswell said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.